- Tags: myopia management
Research
Essilor Stellest 2.0 lenses demonstrate superior efficacy in slowing myopia progression
Upgraded FDA-authorized spectacle lenses for pediatric myopia control found to slow axial elongation more effectively after 1 year with advanced technology.Pipeline
Sydnexis reports phase 3 topline data on SYD-101 eye drop for pediatric myopia
The STAR study met both primary and secondary endpoints for low-dose atropine formulation—just days after the FDA’s NDA rejection.Pipeline
FDA rejects Sydnexis’ NDA for low-dose atropine drop
SYD-101 still has the potential to become the first pharmaceutical option for progressive myopia for patients aged 3 to 14.Products
Myopia Profile debuts AI virtual assistant for disease management
Ask Kate is trained to deliver real-time, evidence-based responses to help ECPs stay updated on the latest clinical and scientific research.Events
GMAC launches free myopia awareness toolkit for ECPs
Downloadable resources include take-home brochures, social media graphics, and more to raise awareness and education of pediatric disease progression.Research
National trial to test preventative atropine drops for pediatric myopia
The University of Houston and The Ohio State University researchers partner on NEI-funded study to test if low-concentrated drops delay onset of myopia.Research
Do seasonal variations impact myopia treatment efficacy?
Researchers investigate whether the effect of orthokeratology varies base don the season.Research
Study identifies risk factors for myopic macular degeneration progression
Axial elongation was shown to be a key risk factor for progression, among others.Pipeline
iVeena submits IND to FDA for pediatric myopia clinical trial
Company plans to initiate a multinational phase 2 study on IVMED-85, a PF and non-atropine daily eye drop intended to improve refraction and decrease AE rates.Pipeline
New DOT lens data finds 75% pediatric myopia management efficacy after 12 months
Latest clinical results support safety and effectiveness of SightGlass Vision’s Diffusion Optics Technology spectacle lenses—including 1-year following discontinued wear.Research
New data supports Hoya's DIMS lenses for myopic prevention among preschool-aged pediatrics
Presented at ARVO, updated findings among the younger pre-myopics confirmed a protective effect of the patented and embedded technology on refractive status.Research
MiSight 1 day lens 7-year data supports long-term myopia control
Clinical study on dual-focus contact lens notes retained treatment gains among myopic eyes even after discontinued wear.Products
Bausch + Lomb launches ortho-k lens fitting system
The Arise cloud-based platform syncs directly with diagnostic tools to create a customized lens design for myopia treatment in mere seconds—without the need for a fitting set.Pipeline
FDA accepts NDA for Sydnexis's low-dose atropine for pediatric myopia
Once-daily drop features unique establishing excipient to avoid rapid atropine degradation; may become first eye drop with 3-year shelf-life.Research
AAO report evaluates validity of multifocal CLs for myopia
Report demonstrates efficacy of multifocal soft CLs for myopia control compared to single-vision spectacles and CLs.Products
Oculus introduces myopia software to Pentacam AXL Wave
Newest software package for optometrists offers improved accuracy and safety for myopia management, screenings, and ortho-k fittings in a single device.Products
Ocumetra showcases all-in-one myopia management software
The mEYE Suite is designed to enhance patient engagement, provide axial length estimates, and enable streamlined decision-making and predictive analytics.Business
CooperVision announces myopia management updates and plans
Company creates new position of Vice President, Myopia Management & Cornea Care and previews clinical investigation plans.Products
Hoya Vision Care launches expanded power range for MiYOSMART lenses for high pediatric myopia
New extension offers spectacles in larger diameters and with optimized lens edge thickness, accommodating both high myopia and astigmatism.Research